Group 1 - The company, Baipusais, announced the approval of two key proposals during its fifth extraordinary shareholders' meeting for 2025, which include the use of remaining raised funds to permanently supplement working capital and the reappointment of the auditing firm for the fiscal year 2025 [2]

Group 1: Eli Lilly - Eli Lilly has submitted a new oral weight loss drug, orforglipron, for FDA approval, indicating a competitive edge in the weight loss medication market [1] - Participants switching from Novo Nordisk's Wegovy to orforglipron maintained most of their weight loss, with an average rebound of only 0.9 kg [1] Group 2: Fosun Pharma - Fosun Pharma's subsidiary has signed a collaboration agreement with Clavis Bio, which could yield up to $363 million in payments [2] - Clavis Bio will have exclusive global rights (excluding mainland China, Hong Kong, and Macau) for development, production, and commercialization of the selected targets [2] - Fosun Pharma will also gain a minority stake in a new project company established by Clavis Bio for this collaboration [2] Group 3: Baidu - Baidu has announced plans to issue H-shares and list on the Hong Kong Stock Exchange to enhance its global strategy and competitiveness [3] - The issuance and listing are subject to shareholder approval and regulatory approvals, with specific details yet to be finalized [3] Group 4: BeiGene - BeiGene has appointed Dr. Wang Lai as the new President and Global Head of R&D, reflecting the company's commitment to innovation in drug development [4] - Dr. Wang has been with BeiGene since 2011 and has progressively taken on more responsibilities in R&D leadership [4] Group 5: Junshi Biosciences - Junshi Biosciences announced that major shareholder Shanghai Tanying plans to reduce its stake by up to 2%, equating to approximately 2,053,380 shares [5] - The reduction is scheduled between January 13, 2026, and April 10, 2026, despite the shareholder's long-term confidence in the company's prospects [5]

Company Announcements - Guo Xin Technology's former actual controller Chen Chongjun was sentenced to six years in prison and fined 4 million yuan for manipulating the securities market [2] - Zhongwei Company is planning to acquire the controlling stake in Hangzhou Zhonggui, leading to a stock suspension [3] - Xusheng Group's controlling shareholder is planning a change of control, resulting in a stock suspension [4] - Yidong Electronics' major shareholders reduced their holdings by 2.3463 million shares between December 10 and December 17 [5] - Nandu Power's controlling shareholder has terminated plans for a change of control, leading to stock resumption [6] - Xibu Mining's subsidiary obtained a mining license for a site with 2.86 tons of gold metal [8] Financial Adjustments - Shandong Highway plans to provision for a long-term equity investment impairment of approximately 690 million yuan related to Dongxing Securities [8] - WuXi AppTec's third and fourth largest shareholders reduced their holdings by a total of 29.508 million shares between November 26 and December 17 [9] Investments and Partnerships - Weixinno plans to sign an investment cooperation agreement to advance the Hefei 8.6 generation AMOLED production line project with a capital of 9.443 billion yuan [10] - Jiangnan New Materials is investing 300 million yuan to build a high-end copper-based core material R&D and industrialization project [15] Shareholding Changes - Sichuan Road and Bridge received a stake increase from Zhongyou Insurance, raising its holding to 5% [11] - Lidasin's fifth largest shareholder reduced their holdings by 1.56% between December 10 and December 17 [12] - Ruicheng Environmental Protection's shareholder plans to reduce their holdings by up to 3% [17] Dividends and Profit Distribution - Haitian Flavoring plans to maintain a cash dividend ratio of no less than 80% for the next three years (2025-2027) [13] - CICC announced a cash dividend distribution of 434 million yuan for the first half of 2025, with a record date of December 26 [14] Financing and Listings - Baipusais plans to issue H-shares and list on the Hong Kong Stock Exchange [21]

（文章来源：证券日报） 证券日报网讯 12月18日晚间，百普赛斯发布公告称，公司第二届董事会第二十四次会议审议通过《关 于公司发行H股股票并在香港联合交易所有限公司上市的议案》《关于公司发行H股股票并在香港联合 交易所有限公司上市方案的议案》《关于公司转为境外募集股份有限公司的议案》等多项议案。 ...

证券日报网讯12月18日晚间，百普赛斯（301080）发布公告称，公司将于2026年1月6日召开2026年第一 次临时股东会。 ...

Core Viewpoint - The company announced plans to issue H-shares and list on the Hong Kong Stock Exchange to enhance its global strategy and competitiveness [2] Group 1 - The company will hold its 24th meeting of the second board on December 18, 2025, to review the proposal for issuing H-shares [2] - The issuance of H-shares aims to further advance the company's globalization strategy [2] - The listing on the Hong Kong Stock Exchange is intended to create an international capital operation platform [2]

Group 1 - The company, Baipusais (301080.SZ), announced on December 18 that it plans to issue H-shares and list on the main board of the Hong Kong Stock Exchange [1][2] - The issuance of overseas listed foreign shares aims to advance the company's global strategic layout and create an international capital operation platform [1][2] - The proposed issuance and listing are subject to approval from the company's shareholders and relevant government and regulatory authorities [1][2]

百普赛斯（301080）(301080.SZ)发布公告，为进一步推进公司全球化战略布局，打造国际化资本运作 平台，提高综合竞争力，公司拟发行境外上市外资股(H股)并申请在香港联交所主板挂牌上市。公司将 充分考虑现有股东的利益和境内外资本市场的情况，在股东会决议有效期内(即经公司股东会审议通过 之日起24个月或同意延长的其他期限)选择适当的时机和发行窗口完成本次发行并上市。 ...

格隆汇12月18日丨百普赛斯(301080.SZ)公布，为进一步推进公司全球化战略布局，打造国际化资本运 作平台，提高综合竞争力，公司拟发行境外上市外资股（H股）并申请在香港联合交易所有限公司（简 称"香港联交所"）主板挂牌上市。公司将充分考虑现有股东的利益和境内外资本市场的情况，在股东会 决议有效期内（即经公司股东会审议通过之日起24个月或同意延长的其他期限）选择适当的时机和发行 窗口完成本次发行并上市。 ...

每经头条（nbdtoutiao）——海南封关首日直击：为中国探路，全球最大自贸港如何重塑开放边界？ （记者 曾健辉） 2024年1至12月份，百普赛斯的营业收入构成为：研究和试验发展占比98.13%，其他业务占比1.87%。 截至发稿，百普赛斯市值为88亿元。 每经AI快讯，百普赛斯（SZ 301080，收盘价：52.41元）12月18日晚间发布公告称，公司第二届第二十 四次董事会会议于2025年12月18日在北京市北京经济技术开发区宏达北路8号公司会议室以通讯表决的 方式召开。会议审议了《关于确定公司董事角色的议案》等文件。 ...